Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC_VEROne in oligometastatic peritoneal gastric cancer
2021-000830-33Phase 3Active
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Aug 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, cisplatin, doxorubicin, folinic acid and 1 more in gastric adenocarcinoma (2 arms), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Secondary resectability rate. Started Aug 2021; status: active.
02
Drugs
oxaliplatinfluorouracilcisplatindoxorubicinfolinic acid
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2021-000830-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000830-33.